RESEARCH · TIRZEPATIDE · GASTRIC EMPTYING
Tirzepatide, Gastric Emptying and Appetite: GI Motility and Intake Readouts in Clinical Research
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist developed as a fatty-acid–modified peptide for once-weekly subcutaneous administration [1]. Our earlier articles cover the SURPASS/SURMOUNT programme overview and imbalanced/biased GIP–GLP-1 receptor pharmacology. This article stays with gastrointestinal pharmacology: what peer-reviewed studies measured for gastric emptying, appetite and energy intake. PurixLab’s Tirzepatide 10mg is a research material for laboratory research use only; nothing here is guidance for human use, and clinical formulations are not the same as a research vial.
Why gastric emptying matters for dual incretins
GLP-1 receptor agonism slows gastric emptying and small-intestinal motility, which can limit postprandial glucose excursions and also contribute to retained gastric contents in procedural settings [2,3]. Reviews of GLP-1-based therapies emphasise tachyphylaxis of the emptying delay with prolonged exposure, residual effects that may persist in some people with type 2 diabetes, and the limited incremental information available when baseline emptying is already slow [2]. For a dual agonist, the open question was whether GIP receptor activity would change that GLP-1-like emptying signature.
Acetaminophen probes: transient delay like selective GLP-1 agonists
Urva and colleagues compared tirzepatide with selective GLP-1 receptor agonists in diet-induced obese mice and in participants from a phase 1, 4-week multiple-ascending study, using acetaminophen absorption as the gastric-emptying surrogate [4]. In mice, tirzepatide delayed emptying to a similar degree as semaglutide, but those acute inhibitory effects were abolished after 2 weeks of treatment; a long-acting GIP analogue alone had no effect on emptying and did not alter GLP-1’s effect [4]. In participants with and without type 2 diabetes, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed emptying after a single administration. That effect diminished after repeated administrations of tirzepatide or dulaglutide in healthy participants, whereas participants with type 2 diabetes on escalation schedules of 5/5/10/10 or 5/5/10/15 mg still showed a residual delay after multiple administrations [4]. The authors conclude that tirzepatide’s gastric-emptying activity is comparable to selective GLP-1 receptor agonists [4].
Appetite, energy intake and body composition
A secondary analysis of a randomised, double-blind, parallel-arm study assessed tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44) and placebo (N = 28) at baseline and week 28 [5]. Tirzepatide reduced body weight versus placebo and semaglutide and produced greater fat-mass reduction; both active arms reduced appetite versus placebo, while appetite scores and energy-intake reductions did not differ between tirzepatide and semaglutide [5]. The authors note that differences in ad libitum lunch energy intake were not sufficient to explain the different weight outcomes and call for further work on 24-h intake, substrate utilisation and energy expenditure [5].
A dedicated 6-week phase 1 ingestive-behaviour trial randomised 114 adults without diabetes and with body-mass index from 27 to 50 kg per m2 to blinded once-weekly tirzepatide or placebo, or open-label once-daily liraglutide [6]. The primary outcome was change from baseline to week 3 in energy intake during an ad libitum lunch: tirzepatide reduced intake versus placebo (estimated treatment difference −524.6 kcal, 95% CI −648.1 to −401.0) [6]. Secondary readouts versus placebo included lower overall appetite, food cravings, tendency to overeat, perceived hunger and reactivity to environmental food cues, without a change in volitional dietary restriction; fMRI signals to high-fat, high-sugar food photos decreased in medial frontal and cingulate gyri, orbitofrontal cortex and hippocampus [6]. Secondary analyses of a related obesity trial with dietary restriction have also examined participant-reported food craving and preference under tirzepatide [7], and a metabolic-adaptation study reported that tirzepatide did not blunt adaptive thermogenesis but increased fat oxidation [8].
Large outcome trials: GI events as the dominant safety signal
In the SURMOUNT-1 obesity trial, 2539 adults received once-weekly tirzepatide at three maintenance levels or placebo for 72 weeks [9]. Mean percentage weight change at week 72 was −15.0%, −19.5% and −20.9% across the three active arms versus −3.1% with placebo, and gastrointestinal events were the most common adverse events, mostly mild to moderate and concentrated during escalation [9]. A narrative review of nutrient intake under GLP-1 receptor agonist therapy summarises how satiety hormones reshape hunger, satiation, satiety and reward eating in clinical practice settings [10]. Those programme-level GI signals are consistent with the mechanism studies above, but they do not replace direct emptying or intake measurements.
What remains open
- Tachyphylaxis versus residual delay. Emptying delay fades with repeated exposure in healthy participants but can leave a residual signal in type 2 diabetes escalation cohorts [4,2].
- GIP does not drive emptying. Mouse data show GIP agonism alone neither slows emptying nor potentiates GLP-1’s effect [4].
- Intake versus weight gap. Ad libitum lunch reductions do not fully account for weight differences versus semaglutide [5].
- Procedural risk evidence is thin. Reviews discuss retained gastric contents and aspiration risk, but controlled evidence for periprocedural management remains limited [2].
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PubMed 30473097 · PMC6308032 · doi:10.1016/j.molmet.2018.09.009
- Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15. PubMed 39418085 · PMC11651700 · doi:10.1210/clinem/dgae719
- Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024;166(1):bqae155. PubMed 39568409 · PMC11630531 · doi:10.1210/endocr/bqae155
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. PubMed 32519795 · PMC7539915 · doi:10.1111/dom.14110
- Heise T, DeVries JH, Urva S, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. PubMed 36857477 · PMC10154650 · doi:10.2337/dc22-1710
- Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025;31(9):3141-3150. PubMed 40555748 · PMC12443625 · doi:10.1038/s41591-025-03774-9
- Kennedy SF, Knights A, Ravussin E, et al. Impact of tirzepatide treatment on participant-reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction. Diabetes Obes Metab. 2025;27(11):6784-6789. PubMed 40874370 · PMC12515769 · doi:10.1111/dom.70063
- Ravussin E, Sanchez-Delgado G, Martin CK, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025;37(5):1060-1074.e4. PubMed 40203836 · doi:10.1016/j.cmet.2025.03.011
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed 35658024 · doi:10.1056/NEJMoa2206038
- Fujioka K. Effect of GLP-1 receptor agonist on nutrient intake: A narrative review. Nutr Clin Pract. 2026;41(5):1308-1317. PubMed 42754546 · PMC13622391 · doi:10.1002/ncp.70172